Zymfentra Market Report 2026

Zymfentra Market Overview

• The Zymfentra market growth in the historic period has been driven by advancements in recombinant enzyme development, improved diagnosis of rare metabolic disorders • Market expansion is supported by increasing investments in rare disease research, rising demand for long-term enzyme therapies • Growth Driver: Impact Of The Aging Population On The Growth Of The Market • Market Trend: Innovative Drug Approvals Driving Advancements In Patient Care • North America was the largest region in 2025.

What Is Covered Under Zymfentra Market?

Zymfentra is a medication used to treat enzyme replacement therapy (ERT) for patients with certain types of rare genetic disorders, specifically those affecting the metabolism of complex sugars. It works by providing the missing or deficient enzyme, helping to reduce symptoms and improve the quality of life for individuals suffering from these disorders. The main types of indications for zymfentra include ulcerative colitis, crohn's disease, and rheumatoid arthritis. Ulcerative colitis is a long-term inflammatory condition that affects the lining of the large intestine and rectum, causing ulcers and irritation. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used by adult and geriatric patients.

What Is The Zymfentra Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in rare disease research, rising demand for long-term enzyme therapies, expansion of homecare treatment models, growing use of digital patient monitoring tools, improved reimbursement frameworks. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, growing focus on rare genetic disorders, expansion of personalized treatment approaches, improved biologic manufacturing processes, rising use of home-based infusion therapies.

Global Zymfentra Market Segmentation

1) By Indication: Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End-User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Zymfentra Market?

The rise in the aging population is expected to propel the growth of the zymfentra market going forward. An aging population refers to an increasing proportion of elderly individuals within a society, typically due to higher life expectancy and declining birth rates. The rise in the aging population is primarily due to the growing life expectancy and declining birth rates. Zymfentra is essential for the aging population as it offers a convenient and effective treatment for managing chronic inflammatory diseases, which are more prevalent with age, reducing the burden of frequent hospital visits. For instance, in October 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, one in six people worldwide will be 60 years or older by 2030, with the population in this age group rising from 1 billion in 2020 to 1.4 billion. By 2050, the global population of individuals aged 60 and above is expected to double, reaching 2.1 billion. Additionally, the number of people aged 80 or older is projected to triple between 2020 and 2050, reaching 426 million. Therefore, the rise in the aging population is driving the growth of the zymfentra industry. The rise in healthcare investments is expected to propel the growth of the zymfentra market going forward. Healthcare investments refer to the allocation of capital into various sectors of the healthcare industry, including pharmaceuticals, biotechnology, medical devices, and healthcare services, with the aim of generating financial returns and advancing medical innovations. The rise in healthcare investments is primarily due to the growing demand for advanced medical services and innovations driven by an aging population and increased health awareness. Increased healthcare investments enhance access to advanced treatments like zymfentra by supporting research, regulatory approvals, and infrastructure for broader patient reach and improved care. For instance, in May 2024, according to the Office for National Statistics, a UK-based government agency, the UK’s total healthcare expenditure reached approximately $366 billion (£292 billion), reflecting a 5.6% increase in nominal terms. Of this, around $299 billion (£239 billion) was financed by the government. Therefore, the rise in healthcare investments is driving the growth of the zymfentra industry.

Key Players In The Global Zymfentra Market

Major companies operating in the zymfentra market are Celltrion Inc.

Global Zymfentra Market Trends and Insights

The key trend in the zymfentra market is obtaining drug approval by authorities to gain a competitive edge in the industry. Drug approval is the process by which regulatory authorities evaluate and authorize a new drug for sale and use, ensuring its safety, efficacy, and quality based on clinical trial data. For instance, in October 2023, Celltrion Inc., a South Korea-based biopharmaceutical company, announced the U.S. Food and Drug Administration approval for Zymfentra (infliximab-dyyb). This subcutaneous version allows patients to self-administer the medication at home, reducing the need for frequent hospital visits and the discomfort associated with intravenous infusions. The approval provides a new option for patients with conditions such as Crohn's disease, rheumatoid arthritis, and psoriasis, offering faster administration, potential cost savings, and improved patient adherence to treatment regimens.

Regional Insights

North America was the largest region in the zymfentra market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Zymfentra Market?

The zymfentra market consists of sales of biosimilars, immunomodulators, monoclonal antibodies and intravenous infusion medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Zymfentra Market Report 2026?

The zymfentra market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the zymfentra industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.